Table 4.
Landmark analyses of overall survival according to timing of bevacizumab discontinuation in patients with glioblastoma multiforme
| Overall survival from landmark | Week 9 |
Week 18 |
Week 26 |
|||
|---|---|---|---|---|---|---|
| LD | ED | LD | ED | LD | ED | |
| Overall population, n | 43 | 5 | 32 | 9 | 21 | 12 |
| Median (95% CI, wk) | 23.0 (17.7-28.3) | 25.0 (17.8-33.1) | 14.3 (8.7-19.8) | 19.0 (16.9-21.1) | 12.9 (2.6-23.1) | 17.6 (5.6-29.5) |
| p (log-rank) | 0.778 | 0.948 | 0.297 | |||
| Adjusted hazard ratio (95% CI)a) | - | 1.13 (0.37-3.43) | - | 1.02 (0.42-2.44) | - | 0.75 (0.31-1.84) |
| p (Wald) | 0.838 | 0.969 | 0.535 | |||
| Patients with CR/PRb), n | 9 | 0 | 10 | 2 | 7 | 5 |
| Median (95% CI, wk) | 63.7 (33.9-93.6) | - | 54.7 (0.0-130.3) | 25.6 | 46.7 (4.0-89.4) | 26.3 |
| p (log-rank) | - | 0.084 | 0.416 | |||
| Patients with SDb), n | 34 | 5 | 22 | 7 | 14 | 7 |
| Median (95% CI, wk) | 20.4 (15.8-25.1) | 21.7 (16.6-26.9) | 9.9 (5.1-14.6) | 18.3 (13.5-23.1) | 6.0 (0.0-13.3) | 10.3 (5.5-15.1) |
| p (log-rank) | 0.383 | 0.194 | 0.641 | |||
LD, late discontinuation; ED, early discontinuation; CI, confidence interval; CR, complete response; PR, partial response, SD, stable disease; ECOG, Eastern Cooperative Oncology Group.
a)
Adjusted for age, ECOG performance scale (0-1 vs. 2-3), number of relapses (1 vs. ≥ 2), and response at each landmark (CR/PR vs. SD),
b)
Response at each landmark.